StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a report published on Thursday. The brokerage issued a hold rating on the biotechnology company’s stock.
Pulmatrix Stock Performance
PULM traded down $0.07 during midday trading on Thursday, reaching $1.96. 6,201 shares of the company were exchanged, compared to its average volume of 17,192. The company has a market cap of $7.15 million, a price-to-earnings ratio of -0.51 and a beta of 0.90. Pulmatrix has a one year low of $1.55 and a one year high of $3.09. The company’s fifty day moving average price is $1.88 and its 200 day moving average price is $1.88.
Pulmatrix (NASDAQ:PULM – Get Free Report) last released its quarterly earnings results on Thursday, March 28th. The biotechnology company reported ($0.57) earnings per share for the quarter. The firm had revenue of $2.20 million for the quarter. Pulmatrix had a negative return on equity of 63.94% and a negative net margin of 193.49%.
About Pulmatrix
Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Featured Stories
- Five stocks we like better than Pulmatrix
- Are Penny Stocks a Good Fit for Your Portfolio?
- MarketBeat Week in Review – 4/29 – 5/3
- Investing in Construction Stocks
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Manufacturing Stocks Investing
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
